• Je něco špatně v tomto záznamu ?

CYP2C19 and CYP3A4 activity and ADP-induced platelet reactivity in prasugrel- or ticagrelor-treated STEMI patients: monocentric study in PRAGUE-18 trial participants

J. Máchal, O. Hlinomaz, K. Kostolanská, O. Peš, A. Máchalová, Z. Šplíchal, Z. Mot'ovská, J. Juřica,

. 2020 ; 50 (8) : 929-938. [pub] 20200330

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20024864

We assessed the contribution of CYP2C19 and CYP3A4 metabolic activity to the ADP-induced platelet aggregation 1h and 24h after a loading dose of 60 mg prasugrel or 180 mg ticagrelor in patients with ST-elevation myocardial infarction (STEMI). Further, we assessed the contribution of CYP2C19 polymorphisms and medication to the CYP enzymatic activity.Patients with STEMI were randomly assigned to the treatment with prasugrel (n = 51) or ticagrelor (n = 46). Metabolic activity of CYP2C19 and CYP3A4 was assessed by the rate of 5-hydroxylation and sulfoxidation of lansoprazole. Further, patients were genotyped for CYP2C19 *2 and *17 alleles.In prasugrel-treated patients, high ADP-induced platelet reactivity 1h after the loading dose positively correlated with 5OH-lansoprazole/lansoprazole ratio (r = 0.44, p = 0.002), a marker of CYP2C19 metabolic activity, and negatively with lansoprazole-sulfone/lansoprazole ratio, which reflects CYP3A4 metabolic activity (r = -0.35, p = 0.018).CYP2C19 poor metabolizers had lower 5OH-lansoprazole/lansoprazole ratio and higher lansoprazole-sulfone/lansoprazole ratio, but without any effect on the ADP-induced platelet reactivity. The treatment with amiodarone, a CYP3A4 inhibitor, influenced neither the metabolic ratios nor the ADP-induced platelet reactivity.The CYP3A4 and CYP2C19 metabolic activity is associated with ADP-induced platelet reactivity in prasugrel-treated, but not ticagrelor-treated patients with STEMI.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20024864
003      
CZ-PrNML
005      
20201222153556.0
007      
ta
008      
201125s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/00498254.2020.1731625 $2 doi
035    __
$a (PubMed)32065000
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Máchal, J $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic. Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
245    10
$a CYP2C19 and CYP3A4 activity and ADP-induced platelet reactivity in prasugrel- or ticagrelor-treated STEMI patients: monocentric study in PRAGUE-18 trial participants / $c J. Máchal, O. Hlinomaz, K. Kostolanská, O. Peš, A. Máchalová, Z. Šplíchal, Z. Mot'ovská, J. Juřica,
520    9_
$a We assessed the contribution of CYP2C19 and CYP3A4 metabolic activity to the ADP-induced platelet aggregation 1h and 24h after a loading dose of 60 mg prasugrel or 180 mg ticagrelor in patients with ST-elevation myocardial infarction (STEMI). Further, we assessed the contribution of CYP2C19 polymorphisms and medication to the CYP enzymatic activity.Patients with STEMI were randomly assigned to the treatment with prasugrel (n = 51) or ticagrelor (n = 46). Metabolic activity of CYP2C19 and CYP3A4 was assessed by the rate of 5-hydroxylation and sulfoxidation of lansoprazole. Further, patients were genotyped for CYP2C19 *2 and *17 alleles.In prasugrel-treated patients, high ADP-induced platelet reactivity 1h after the loading dose positively correlated with 5OH-lansoprazole/lansoprazole ratio (r = 0.44, p = 0.002), a marker of CYP2C19 metabolic activity, and negatively with lansoprazole-sulfone/lansoprazole ratio, which reflects CYP3A4 metabolic activity (r = -0.35, p = 0.018).CYP2C19 poor metabolizers had lower 5OH-lansoprazole/lansoprazole ratio and higher lansoprazole-sulfone/lansoprazole ratio, but without any effect on the ADP-induced platelet reactivity. The treatment with amiodarone, a CYP3A4 inhibitor, influenced neither the metabolic ratios nor the ADP-induced platelet reactivity.The CYP3A4 and CYP2C19 metabolic activity is associated with ADP-induced platelet reactivity in prasugrel-treated, but not ticagrelor-treated patients with STEMI.
650    _2
$a adenosindifosfát $x metabolismus $7 D000244
650    _2
$a cytochrom P450 CYP2C19 $x metabolismus $7 D065731
650    _2
$a cytochrom P-450 CYP3A $x metabolismus $7 D051544
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a prasugrel hydrochlorid $x farmakologie $x terapeutické užití $7 D000068799
650    _2
$a infarkt myokardu s elevacemi ST úseků $x farmakoterapie $7 D000072657
650    _2
$a ticagrelor $x farmakologie $x terapeutické užití $7 D000077486
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hlinomaz, O $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic.
700    1_
$a Kostolanská, K $u Department of Biochemistry, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Peš, O $u Department of Biochemistry, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Máchalová, A $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Šplíchal, Z $u Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Mot'ovská, Z $u Cardiocenter, Third Faculty of Medicine, Charles University and University Hospital, Prague, Czech Republic.
700    1_
$a Juřica, J $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. Masaryk Memorial Cancer Institute, Brno, Czech Republic.
773    0_
$w MED00004746 $t Xenobiotica; the fate of foreign compounds in biological systems $x 1366-5928 $g Roč. 50, č. 8 (2020), s. 929-938
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32065000 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222153552 $b ABA008
999    __
$a ok $b bmc $g 1599009 $s 1115550
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 50 $c 8 $d 929-938 $e 20200330 $i 1366-5928 $m Xenobiotica $n Xenobiotica $x MED00004746
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace